Returning guest, Dr. Steve Tilles, Senior Director of Medical Affairs at Aimmune Therapeutics, the first company to gain FDA approval of a peanut allergy treatment, PALFORZIA™, discusses his experience as an allergist, where the allergy immunology market is headed over the next year and provides real-world insight into practices reopening in light of COVID-19.
Stephen A. Tilles, MD, is Senior Director of Medical Affairs at Aimmune Therapeutics. In addition to this role, he is a Fellow of the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma, and Immunology (ACAAI). Previously, he served as President of the ACAAI. Dr. Tilles has been a principal investigator for more than 140 clinical trials involving treatments for asthma, allergic rhinitis, urticaria and atopic dermatitis, as well as 13 trials evaluating treatments for food allergy. He has authored more than 100 papers in peer-reviewed publications. He has appeared on various lists including “Seattle’s Best Doctors”, “Seattle Super Doctors”, “Washington’s Best Doctors”, and “America’s Best Doctors”.